key: cord-0771012-6b3ymmfc
authors: Pitlick, Mitchell M.; Gonzalez-Estrada, Alexei; Park, Miguel A.
title: Graded COVID-19 Vaccine Administration: A Safe Alternative to Vaccine Avoidance
date: 2022-03-04
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2022.02.024
sha: 71da5de9abb7682f92bac4ba5abd64b8776e820d
doc_id: 771012
cord_uid: 6b3ymmfc

nan

these concerns was previously outlined, but subsequent studies showed limited utility in its use. [1] [2] [3] Emphasis has now shifted towards methods of safe vaccine administration in patients with concern for vaccine allergy in a model consistent with existing vaccine allergy practice parameters. [4] [5] There is minimal reported experience using graded dosing protocols for COVID-19 vaccine administration. One case report described two patients with an immediate reaction the first dose of the Moderna COVID-19 vaccine who successfully received their 2 nd dose using a 5-step protocol. 6 This protocol, along with a 4-step protocol for the Pfizer-BioNTech vaccine, were used in 16 patients in a separate report, with two patients experiencing anaphylaxis at the end of the graded dosing protocol. 7 A separate series utilized a 2-step protocol for administering the Pfizer-BioNTech COVID-19 vaccine in 12 patients. 8 One patient received levocetirizine for pruritus, but all 12 patients successfully completed the protocol without anaphylaxis. 8

In this report, we describe multiple dosing protocols for all three currently available COVID-19 vaccines in the US. In this multi-center retrospective review, over 30 adult patients referred to the Mayo Clinics in Rochester, MN, Scottsdale, AZ, and Jacksonville, FL received a COVID-19 vaccine via a graded dosing protocol. The need for graded dosing and the protocol used were provider-determined at the time of evaluation. Following the graded dosing, patient charts were reviewed to extract demographic characteristics, reason for graded dosing, prior COVID-19 vaccine reaction, and graded dosing outcome. The primary outcome was successful completion of graded dosing. Data were analyzed using BlueSky Statistics Software v7.2 (BlueSky Statistics LLC, Chicago, IL, USA). Statistical comparisons were made between those who experienced symptoms with graded dosing, and those who did not. Continuous variables between groups were compared using independent group t tests. Proportions of categorical variables between groups were compared using Fisher's exact test. Results were deemed significant when a two-sided p-value was less than .05.

Between 5/13/21 and 12/31/21, 42 COVID-19 vaccine graded dosing protocols were performed in 36 patients, with 6 patients undergoing two separate graded dosing protocols. Demographic characteristics and vaccination details are shown in Table 1 . The most common indication for a graded dosing protocol was a previous COVID-19 vaccine reaction (n=23) followed by patient concern for multiple drug allergies (n=8), prior non-COVID-19 vaccine reaction (n=6), and mast cell disease (n=5). The Pfizer-BioNTech and Moderna vaccines were most commonly used (n=20 and 17, respectively) followed by Johnson & Johnson (n=5). A 2-step protocol was most frequently employed (n=21) followed by 3 and 4-step (n=10 each), and 5-step (n=1). Six patients reported symptoms during the graded dosing protocol, with 2 of these patients experiencing symptoms during separate graded dose administrations. One patient developed urticaria without other systemic symptoms within 30 minutes of finishing two separate graded dosing protocols that were both successfully treated with diphenhydramine. One patient experienced subjective chest tightness without wheezing during two separate graded dosing protocols that were both successfully treated with albuterol. Four other patients experienced either pruritus (n=2), nasal congestion (n=1), or cough (n=1) without any objective findings. No patient experienced changes in vital signs during the graded dosing protocol. All 42 graded dosing protocols were successfully completed with no cases of anaphylaxis. There were no significant differences in vaccine used, graded dosing indication, or dosing protocol in those who reported symptoms during the graded dosing protocol compared to those who did not. There was a significantly higher prevalence of allergic rhinitis (p=.01) and patient-reported food allergy history (p=.04) in those who had symptoms during the graded dosing protocol compared to those who did not. 

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing

Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions

The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, metaanalysis, GRADE assessment, and international consensus approach

Adverse reactions to vaccines practice parameter 2012 update